Named on 5 rounds in the feed, most often in Biotech.
Rounds from 2023-11-14 to 2026-10-19
ROUNDS
5
joined, none as lead
ROUNDS JOINED · USD
$458.0M
across 5 rounds
CO-INVESTORS
25
named beside it
Named on 5 rounds in the feed, most often in Biotech.
Rounds from 2023-11-14 to 2026-10-19
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Nouscom Nouscom is a biotech company selling cancer-preventing vaccine candidates primarily to healthcare providers and clinical trial organizations. | Series D Verified against 4 of 10 sources | $133.8M | 2026-10-19 | [ PART ] |
Nouscom A clinical-stage, cancer interception focused biotech developing next-generation immunotherapies | Series D Verified against 4 of 41 sources | $134.7M | 2026-10-19 | [ PART ] |
Aptadir Therapeutics A preclinical biotech company developing a new class of RNA therapeutics | Seed Verified against 1 of 40 sources | $44.7M | 2026-09-29 | [ PART ] |
Nouscom Nouscom is a biotech company selling cancer-preventing vaccine candidates primarily to healthcare providers and clinical trial organizations. | Series C Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $72.4M | 2023-11-14 | [ PART ] |
Nouscom A clinical-stage, cancer interception focused biotech developing next-generation immunotherapies | Series C Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $72.4M | 2023-11-14 | [ PART ] |